GENOMIC TESTING

Barriers to improving BRAF testing turnaround time in patients with melanoma have been identified in a retrospective analysis of real-world data collected in Canada.

Next-generation sequencing provides oncologists with accurate information in a cost-effective manner, thereby affording treatment options we would not otherwise have.

The FDA approved the BRACAnalysis CDx test for use as a companion diagnostic with adjuvant olaparib to identify patients with germline BRCA-mutated for patients with HER2 negative, high-risk early-stage breast cancer.

Findings from the GALAHAD clinical trial highlight the importance of molecular testing to inform treatment and disease management decision for prostate cancer.

There are still a lot of things that are ongoing, and the myeloma field is evolving with new treatments, according to Mark Bustoros, MBBCh.

With an increase in genomic testing for colorectal cancer, new targeted treatments have also been developed to treat patients with specific disease characteristics.

A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.

Genomic testing has grown in importance as the number of targeted anticancer therapies rises. Early genomic testing can help to guide treatment choices.

In an interview with Targeted Therapies in Oncology, Nicholas J. Robert, MD, discussed what the results to date of the MYLUNG study mean for patients with non–small cell lung cancer.

A new database organizes information on driver mutations for researchers.

A 59-year-old man presented with dyspnea on exertion, fatigue, anorexia, and a 5-lb weight loss. He received the diagnosis of stage IVA adenocarcinoma and had an ECOG performance status of 1.

Florida Cancer Specialists & Research Institute has expanded its molecular testing capabilities at its state-of-the-art Pathology Laboratory in Fort Myers and is providing patients with clinical next-generation sequencing.

Today, many community oncology practices routinely employ genetic testing, enabling newly diagnosed patients and their oncologists to make treatment decisions and to formulate preventive strategies based on genetic information.

During a Targeted Oncology Case-Based Roundtable event, Grace K. Dy, MD and 9 other physicians discussed molecular testing for patients with non–small cell lung cancer.

Michael J. Overman, MD, discusses the advances in testing for rare genomic alterations in colorectal cancer.

Potentially clinically actionable genomic alterations were identified in a majority of patients with advanced cancers with next-generation sequencing evaluated in a prospective study.

Novel methods of genetic testing have led to improved detection and better clinical decisions in patients with melanoma, especially in the late-stage setting.

As the understanding of genetic risk factors in breast cancer continues to grow, professional organizations have sought to provide specific recommendations for genetic testing that would prevent overtesting yet still diagnose as many mutations as possible in patients.

The FDA has granted approval to the VENTANA ALK CDx Assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who may be eligible for treatment with the recently approved ALK inhibitor lorlatinib.

During a Targeted Oncology Case-Based Peer Perspectives event, Arash Rezazadeh Kalebasty, MD, discussed genomic testing and evidence-based treatment of a 60-year-old male patient with prostate cancer.

During a debate at the 27th Annual Prostate Cancer Foundation Virtual Scientific Retreat, Daniel Spratt, MD, debated Daniel Lin, MD, on the subject of genomic classifiers in prostate cancer.

In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.

The Access to Comprehensive Genomic Profiling Coalition has been formed by 7 leading diagnostic companies and laboratory providers across the United States to advocate for appropriate broad health insurance coverage of comprehensive genomic profiling for patients with advanced-stage cancer.

A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.